Saturday, July 11, 2026

pharma · COPD (Chronic Obstructive Pulmonary Disease) · Uncontrolled Asthma

Chiesi Farmaceutici S.p.A

Chiesi Farmaceutici S.p.A clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Parma, IT HQ
6,080 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Parma, IT
Employees
6,080
Programs
2
Drugs
3
Patents
0
Intelligence · Clinical Programs

Chiesi Farmaceutici S.p.A projects

2 ClinicalTrials.gov programs sponsored by Chiesi Farmaceutici S.p.A.

Chiesi Farmaceutici S.p.A has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CHF 5993 100/6/12.5 µg

    Chiesi Farmaceutici S.p.A.

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 3 small molecule completed

    1 trial
  2. Experimental: CHF6001 3200 μg

    Chiesi Farmaceutici S.p.A.

    Uncontrolled Asthma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Chiesi Farmaceutici S.p.A have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.